Liriodenine is a natural alkaloid that induces apoptosis in various cancer cells by targeting caspase-3 and caspase-9, and exhibits antimicrobial, antifungal, antitumour, antiviral, and antiplatelet aggregation activities.

HT-29 cells:11.02 μM, MLKL (HT-29 cells):11.02 μM, HEK-293 cells:8.07μM, KB cells:9.60 μM, A549 cells:9.20 μM

Methods: Liriodenine (0.16-20 μg/mL, 48 hours) was used to treat human oral epidermoid carcinoma (KB), human colon cancer (Col-2 and HT-29), human breast cancer (MCF-7), human lung cancer (Lu-1 and A549), rat glioma (ASK), and noncancerous human embryonic kidney cells (HEK-293), and cytotoxicity was determined using the sulforhodamine B assay.
Results: Liriodenine showed IC50 values ​​of 9.60 μM, 11.02 μM, 10.62 μM, 9.20 μM and 8.07 μM for KB, HT-29, MCF-7, A549, ASK, and HEK-293 cells, respectively. [2]

Methods: Liriodenine (0.01, 0.1 mg/kg, intravenous) was administered to rats to determine whether the effective antiarrhythmic dose of 0.01 mg/kg liriodenine has an effect on left ventricular (LV)-arterial coupling in Wistar rats.
Results: Liriodenine at a dose of 0.01 mg/kg did not cause significant changes in basal heart rate (HR), cardiac output (CO), LV end-systolic pressure (Pes), Ea, Ees, and Q load, whereas liriodenine at a dose of 0.1 mg/kg caused a significant decrease in HR by 2.0%, a significant increase in CO by 5.8%, but no significant change in Pes. In addition, administration of 0.1 mg/kg liriodenine to rats significantly decreased Ees by 8.5% and Ea by 10.6%, but did not change Q load. [3]